Home Page |
References | OMIM | Gene | GeneReviews | HGMD | HGNC |
GENATLAS PHENOTYPE |
last update : 08-01-2019 |
Symbol | GEFSP2 |
Location | 2q24.3 |
Name | generalized epilepsy with febrile seizures plus, 2 |
Corresponding gene | SCN1A , SCN9A |
Other symbol(s) | GEFS2,GEFS+, FHM3 |
Main clinical features |
|
Genetic determination | autosomal dominant |
Related entries | . including familial simple febrile seizures, and familial hemiplegic migraine-3 (OMIM 609634) |
Function/system disorder | neurology |
Type | disease |
Gene product |
Name | sodium voltage gated channel I alpha, sodium channel voltage-gated type 2 alpha 1 polypeptide |
Mechanism(s) |
Gene mutation | Chromosome rearrangement | Effect | Comments |
| other
|  
| truncated protein
|  
| missense
|  
| abnormal protein/loss of function
| M145T is a loss-of-function mutant associated to febrile seizures
| |
Remark(s) |
more than 70% of patients with Dravet syndrome have mutations of SCN1A; these include both truncation and missense mutations. In contrast, only 10% of GEFS+ families have SCN1A mutations and these comprise missense mutations. GEFS+ has also been associated with mutations of genes encoding the sodium channel beta 1 subunit, SCN1B, and the GABA(A) receptor gamma 2 subunit, GABRG2. The phenotypic heterogeneity that is characteristic of GEFS+ families is likely to be due to modifier genes
|